Plans & pricing
Pay per event, or go always-on. Credits do the one-off work — your watchlist never sleeps.
Radar
Radar + Events
Event Pass
Add-ons
Always-on radar
Radar
$490 / mo
Monthly · cancel anytime
✓1,000 credits / month
✓Watchlist: 100 companies, signals every week
✓Add companies & people from scratch
✓2 seats
✗Events sold separately
Always-on radar
Radar Pro
$990 / mo
Monthly · cancel anytime
✓2,000 credits / month
✓Watchlist: 250 companies, signals every week
✓Add companies & people from scratch
✓5 seats
✗Events sold separately
Most popular
Radar + events
Always-On
$1,500 / mo
Billed annually · $18,000/yr
✓10 events / year included
✓2,000 credits / month
✓Watchlist: 250 companies, all year
✓5 seats
✓Priority support
Radar + events
Always-On Pro
$2,500 / mo
Billed annually · $30,000/yr
✓20 events / year included
✓2,500 credits / month
✓Watchlist: 500 companies, all year
✓10 seats
✓Priority support
Per event
Event Pass
$2,000 / event
One-time purchase
✓Every fit company at the event — scored, with approach angles
✓Full attendee enrichment
✓Weekly signals until event date
✓2 seats
✗No credits — adding companies requires Radar
Doing 6+ events a year? Always-On wins →
⚡
Credit top-up
from $150$0.75/credit · min 200
⚇
Extra seat
$50/moShares workspace credits & watchlist
★
+50 watchlist slots
$150/moMore companies on weekly signals
How credits work
Add a company — fit score + approach angles + 3 ideal people, fully enriched5 credits
Extra ideal person — one more suggested delegate, fully enriched1 credit
Find a specific person — you name them, we find & enrich1 credit
Company preview · universe scan · ★ watchlist signals · re-score after profile editsFree
Credits reset monthly (no rollover) · seats share the workspace balance · watchlist companies don't consume credits — they're covered by your plan's slots. One workspace = one commercial profile; separate business units run as separate workspaces.
Find your next event
Search by name, or find where a target company is exhibiting.
By nameBy exhibitor
Have a list from a small event or roadshow? Run Lenga intelligence on your own data.
⚲ Location Any ▾
▤ Industry Biotech ▾
⚇ Size Any ▾
◷ Date Upcoming ▾
★ Quality Any ▾
★ RecommendedBIO 2026
BIO International Convention 2026
1,691 fit for you
◷ Upcoming dataDxPx US 2026
DxPx US 2026
est. 420 fit
◷ Upcoming dataCPHI 2026
CPHI Milan 2026
est. 3,100 fit
BIO International Convention 2026 ↗
Biotech's largest global gathering — ~20,000 leaders across pharma, research and investment.
✦ 5,151 companies · 1,691 fit for you
✓ Unlocked · full access
Weekly signals run until Jun 22 · 10 events/yr with Always-On →
Dashboard
Companies
People
Fit criteria
Companies scored
5,151
every exhibitor, vs your ICPFit · score 6+
1,691
worth pursuingTop-fit · 9+
210
elite matchesWith active signals
47
moved in last 30 daysOn watchlist
23
tracked for signalsMeetings booked
1
from this eventBy modality
of 1,691 fit1,691fit
ADC 612
Antibody 430
Small molecule 388
Cell & gene 261
By stage
of 1,691 fitBy fit score
6+ is worth pursuing3,460 scored below 6 — filtered out of your fit pool.
Active signals
across 47 companies47signals
Clinical 21
Grants 9
Funding 8
Job update 5
Supplier risk 4
| Company | Modality | Stage | Also attended | In-market | Fit | Status | |
|---|---|---|---|---|---|---|---|
| ★ | AT Antharis Therapeutics San Diego, US |
ADC | Phase 2 | CPHI Milan | High | 9.5 | Contacted ▾ |
| ★ | PR Prolynx San Francisco, US |
ADC | Phase 2 | — | Med | 8.2 | To review ▾ |
| ★ | OM Oxford Medical Products Oxford, UK |
Small Molecule | Phase 1 | DxPx US | Med | 7.4 | Meeting ▾ |
| ★ | AC Actinium Pharmaceuticals New York, US |
Antibody | Phase 2 | JPM 2027 | Low | 4.8 | To review ▾ |
| ★ | IX invoX Pharma London, UK |
Small Molecule | Phase 2 | — | Low | 3.5 | Not a fit ▾ |
| ★ | NV Nuvation Bio San Francisco, US | Small Molecule | Phase 1 | — | Low | 5.6 | To review ▾ |
| ★ | KY Kymera Bio Boston, US | ADC | Preclinical | DxPx US | Med | 7.1 | To review ▾ |
To review 2
★Prolynx8.2
ADC · Phase 2
★Actinium Pharma4.8
Antibody · Phase 2
Contacted 1
★Antharis Therap.9.5
ADC · Phase 2
Meeting booked 1
★Oxford Medical7.4
Small Molecule · UK
Not a fit 1
★invoX Pharma3.5
Small Molecule · UK
| Person | Company | Role | Seniority | Attended | Contact | |
|---|---|---|---|---|---|---|
| ★ | ER Dr. Elaine Ross VP, CMC · ex-Helvex Biologics |
Antharis Therapeutics 9.5 |
CMC · decision-maker | VP | BIO 2026 | LinkedIn ↗ |
| ★ | IG Imroz Ghangas VP Global Commercial Sales |
Antharis Therapeutics 9.5 |
Commercial | VP | BIO 2026 | LinkedIn ↗ |
| ★ | SK Sarah Kwon VP Manufacturing |
Oxford Medical 7.4 |
CMC · decision-maker | VP | BIO 2026 | LinkedIn ↗ |
| ★ | MF Marco Feltrin Head of Business Development |
Prolynx 8.2 |
BD | Director | BIO 2026 | LinkedIn ↗ |
| ★ | AV Dr. Anja Vogel Chief Scientific Officer |
Kymera Bio 7.1 |
R&D | C-level | BIO 2026 | LinkedIn ↗ |
| ★ | DO David Osei Director, Technical Operations |
Nuvation Bio 5.6 |
CMC · decision-maker | Director | BIO 2026 | LinkedIn ↗ |
| ★ | PN Priya Nair Head of Partnerships |
Actinium Pharmaceuticals 4.8 |
BD | Head | BIO 2026 | LinkedIn ↗ |
| ★ | SD Sybil Danby VP Business Development |
Antharis Therapeutics 9.5 |
BD | VP | BIO 2026 | Not found |
People are enriched for the companies you've analyzed. For CDMO deals, the buyer usually sits in CMC, Tech Ops or BD — those are flagged as decision-makers.
What defines a fit for you
These criteria come from your profile and drive every company's score. Tune them in Settings → Profiling.
▲ Raises fit
Antibodies & protein therapeutics +3.0
Complex small molecules +3.0
Oncology — ADC / degrader focus +3.0
Seeking a CRO/CDMO partnership +1.5
Explicit outsourcing / partnering intent +1.5
Preclinical → clinical / IND-enabling +1.5
Preclinical / Phase I–II stage +1.2
▼ Lowers fit
Competing CRO/CDMO — same services −6.0
Equipment / reagent supplier −3.0
Pure analytical / testing CRO −1.0
Diagnostic / imaging (not therapeutic) −0.8
Discovery-stage only, no candidate −0.8
Platform / tech provider (non-therapeutic) −0.6
Generic / vague language −0.4
Companies directory
Every company Lenga knows from your events — plus any you add yourself.
6,204
companies
1,691
fit for you · score 6+
23
on watchlist
684
attended 2+ events
| Company | Modality | Stage | Attended | In-market | Fit | Status | |
|---|---|---|---|---|---|---|---|
| ★ | AT Antharis Therapeutics San Diego, US |
ADCBispecificSmall Molecule | Phase 2Phase 1Preclinical | BIO 2026 | High | 9.5 | Contacted |
| ★ | OM Oxford Medical Products Oxford, UK |
Small Molecule | Phase 1 | BIO 2026 DxPx | Med | 7.4 | Meeting |
| ★ | PR Prolynx San Francisco, US |
ADC | Phase 2 | BIO 2026 | Med | 8.2 | To review |
| ★ | MK Merck KGaA Darmstadt, DE · you added |
6 modalities | CommercialPhase 3+2 more | Manual add | — | — | |
| ★ | GM Genmab Copenhagen, DK |
AntibodyBispecific | CommercialPhase 3 | BIO 2026 | — | — | |
| ★ | HB Helvex Biologics Basel, CH |
CDMO | — competitor | BIO 2026 | — | — |
Search finds any of the 6,204 companies from your events · ＋ Add company runs the pipeline on one you name (even if it's not exhibiting anywhere).
People directory
Everyone Lenga has enriched across your events — the humans behind the companies.
1,240
people
184
CMC decision-makers
1,090
reachable · email or LinkedIn
96
attended 2+ events
| Person | Company | Role | Seniority | Location | Attended | Contact | |
|---|---|---|---|---|---|---|---|
| ★ | ER Dr. Elaine Ross VP, CMC · ex-Helvex Biologics |
Antharis Therapeutics 9.5 |
CMC · decision-maker | VP | San Diego, US | BIO 2026 | LinkedIn ↗ |
| ★ | SK Sarah Kwon VP Manufacturing |
Oxford Medical 7.4 |
CMC · decision-maker | VP | Oxford, UK | BIO 2026 DxPx | LinkedIn ↗ |
| ★ | IG Imroz Ghangas VP Global Commercial Sales |
Antharis Therapeutics 9.5 |
Commercial | VP | London, UK | BIO 2026 | LinkedIn ↗ |
| ★ | MF Marco Feltrin Head of Business Development |
Prolynx 8.2 |
BD | Director | San Francisco, US | BIO 2026 | LinkedIn ↗ |
| ★ | SD Sybil Danby VP Business Development |
Antharis Therapeutics 9.5 |
BD | VP | — | BIO 2026 | Not found |
People persist across events — the same contact carries their company, role, notes and tags wherever you find them.
Assets
Every drug asset in development across the companies Lenga tracks — molecule, target, phase and who's making it.
3,940
assets tracked
1,204
owned by fit companies
612
early-stage · Preclinical–Ph1
438
no CDMO named
| Asset | Company | Modality | Phase |
|---|---|---|---|
ATH-224 |
Antharis Therapeutics 9.5 | ADC | Phase 2 |
Modality ADC Pipeline page ↗ Target / MoA HER2 Pipeline page ↗ Indication Oncology · Breast, gastric Pipeline page ↗ Phase Phase 2 ClinicalTrials.gov ↗ Latest milestone Ph 1→2 · 2d ago ClinicalTrials.gov ↗ CDMO status No CDMO named Lenga · inferred | |||
PLX-038 |
Prolynx 8.2 | ADC | Phase 2 |
Modality ADC Pipeline page ↗ Target / MoA TOPO-1 Pipeline page ↗ Indication Oncology · Ovarian, SCLC Pipeline page ↗ Phase Phase 2 ClinicalTrials.gov ↗ Latest milestone Dosing update · 3d ago Press release ↗ CDMO status Scouting Lenga · inferred | |||
OMP-115 |
Oxford Medical 7.4 | Small Molecule | Phase 1 |
Modality Small Molecule Pipeline page ↗ Target / MoA GLP-1R Pipeline page ↗ Indication Metabolic · Obesity, T2D Pipeline page ↗ Phase Phase 1 ClinicalTrials.gov ↗ Latest milestone Supply scale-up · 1w ago Press release ↗ CDMO status Scouting Lenga · inferred | |||
KYM-012 |
Kymera Bio 7.1 | ADC | Preclinical |
Modality ADC Pipeline page ↗ Target / MoA TROP2 Pipeline page ↗ Indication Oncology · NSCLC Pipeline page ↗ Phase Preclinical ClinicalTrials.gov ↗ Latest milestone IND-enabling · 2w ago Company pipeline ↗ CDMO status No CDMO named Lenga · inferred | |||
NUV-868 |
Nuvation Bio 5.6 | Small Molecule | Phase 1 |
Modality Small Molecule Pipeline page ↗ Target / MoA BRD4 Pipeline page ↗ Indication Oncology · Solid tumors Pipeline page ↗ Phase Phase 1 ClinicalTrials.gov ↗ Latest milestone Trial initiated · 3w ago ClinicalTrials.gov ↗ CDMO status Scouting Lenga · inferred | |||
AC-225-CD33 |
Actinium Pharma 4.8 | Antibody | Phase 2 |
Modality Antibody Pipeline page ↗ Target / MoA CD33 Pipeline page ↗ Indication Oncology · AML Pipeline page ↗ Phase Phase 2 ClinicalTrials.gov ↗ Latest milestone Trial ongoing · 1mo ago ClinicalTrials.gov ↗ CDMO status In-house Lenga · inferred | |||
Assets link to their owning company. Early-stage assets in modalities you make — especially with no CDMO named — are your clearest manufacturing openings.
Good morning, Andrew
Your event pipeline at a glance.
in-market now
3
↑ 1 vs last week
Companies with fresh signals worth acting on right now.
Pipeline momentum
in-market accounts · last 8 weeks↑ 200% vs month agoSignals this month
8signals
Clinical 3
Grants 2
Funding 1
Job update 1
Supplier risk 1
Latest signals
Open Radar →Antharis Therapeutics
Advanced Phase 1 → Phase 2
Corvus Bio — switching window
Their CDMO received an FDA 483
Sanivon Bio — $60M Series B
No CDMO announced — greenfield
Genmab
New bispecific program added to pipeline
BIO International Convention 2026
Medical & Pharma
Biotech
Investment
Biotech's largest global gathering — ~20,000 leaders across pharma, research and investment. Jun 22–25 · San Diego.
5,151
companies
10,165
attendees
1,691
fit for you
Your profile
Manage your account, notifications and connected tools.
AC
Andrew Cole
VP Business Development · Riverside MFG
Full name
Company
Role / title
Phone
Time zone
Password
New password
Confirm
Notifications
In-market alerts
Ping me when a tracked account turns in-market
Weekly signal digest
Every Monday, by email
Event reminders
When a tracked account registers for an event
Your team
Riverside MFG workspace · shared credits, watchlist & CRMAC
Andrew Cole (you)
OwnerVP Business Development
AV
Alan Valicenti
MemberBusiness Development
MC
Maria Castro
MemberCMC / Tech Ops
JL
James Lee
InvitedBusiness Development · invite pending
Connected CRM
Salesforce
Riverside MFG workspace
Notes & activity sync both ways
Radar
Live signals on the 23 companies on your watchlist — ranked by how in-market they are.
In-market now
3
↑ 1 vs last weekNew signals · 7 days
8
↑ 3 vs prior weekAvg fit · in-market
7.9
across active accountsFit × Timing map
your 23 watchlist accountsi● Act now● Keep watching● Switching window
Signal momentum
signals / week · last 8 weeks↑ 200% vs month agoPrimary (leading)SwitchingInferred
In-market companies
ranked by in-market signals × your fiti1
In-market
Antharis Therapeutics 9.5 fit
Phase 1→2 2d
SBIR grant 1w
New VP CMC 3w
3 primary signals in 30 days · ADC matches your conjugation capability · no CDMO announced
2
In-market
Prolynx 8.2 fit
Phase 2 dosing 3d
Readout due ~Q4 inferred
Clinical milestone + readout approaching · scale-up decision window opening
3
In-market
Corvus Bio 6.1 fit
Their CDMO got FDA 483 5d
Switching window — incumbent supplier flagged · second-source opening
Refresh pulls fresh signals for your 23 watchlist companies · free, once a day.